HCV + HBV + HDV coinfection
 

High prevalence of Dual or Triple Infection of Hepatitis B, C and Delta Viruses among Patients with Chronic Liver Disease in Mongolia

Mongolia is known for its high endemicity for hepatitis B virus (HBV), hepatitis C virus (HCV), and hepatitis delta virus (HDV) infections among apparently healthy individuals. However, there are little or no data on the prevalence and genotype distribution of HBV, HCV, and HDV among patients with chronic liver disease in Mongolia.

Therefore, serum samples obtained in 2004 from 207 patients including those with chronic hepatitis (n = 90), liver cirrhosis (n = 41), and hepatocellular carcinoma (n = 76) were tested for serological and molecular markers of HBV, HCV, and HDV infections.

Results

Of the 207 patients, 144 (69.6%), 106 (51.2%), and 117 (56.5%) tested positive for hepatitis B surface antigen (HBsAg) and/or HBV DNA, HCV RNA, and HDV RNA, respectively.

Collectively, 172 patients (83.1%) were viremic for one or more of these viruses, including dual viremia of HBV/HDV (26.6%) or HBV/HCV (7.7%) and triple HBV/HCV/HDV viremia (30.0%).

Of note, triple ongoing infection was significantly more frequent among patients with hepatocellular carcinoma than among those with chronic hepatitis (63.2% vs. 14.4%, P < 0.0001).

One hundred sixty patients (77.3%) had a history of blood transfusion and/or surgery.

The distribution of HBV genotypes among the 116 HBV-viremic patients was: A (0.9%), B (0.9%), C (6.0%), D (88.8%), and C plus D (3.4%).

All 117 HDV isolates were classified into genotype I.

The 106 HCV RNA-positive samples were typed as genotype 1b (92.5%), 2a (0.9%), or 1b plus 2a (6.6%);

Mixed infection of two distinct HCV genotypes was found exclusively in the patients with hepatocellular carcinoma.

Division of Virology, Department of Infection and Immunity, Jichi Medical School, Tochigi-Ken, Japan.

10/31/05

Reference
B Tsatsralt-Od. High prevalence of dual or triple infection of hepatitis B, C, and delta viruses among patients with chronic liver disease in Mongolia. Medical Virology 77(4):491-499. October 27, 2005 [Epub ahead of print].




All HCV Topics
 [ A to Z ]


2-log Drop
Acute (Primary) HCV Infection
Age
Alcohol / Smoking / Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Cirrhosis
Cognitive Behavioral Therapy
Complementary Therapies (CAM)
Combination Treatment
Cryoglobulinemia / Cryoglobulin
Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dosing
Drug Abuse
Drug Pricing

Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response

Epidemiology / African Americans
Epoetin Alpha
Early Viral Response (EVR)
Eradication
Extrahepatic Events
Experimental Treatment
Experimental Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype 1 and 4
Genotype 2 and 3
Genotype 5 and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines

HCV Clearance
HCV Disease Progression
HCV-Drug Related Adverse Events
HCV Recurrence After Transplantation
Hearing
Hematological Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular Carcinoma
Histology

Hormone Therapies
hyaluronate (HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug Use
Infergen
Insulin Resistance
Interferon
Interferon Resistance
Intron A
Kidney Disorders
Kidney Transplant

Liver Biopsy
Liver Enzymes
Liver Issues
Living Donors
Liver Stiffness Measurement (LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity

Monotherapy Treatment

Mother to Child Transmission of HCV
Natural History
Neutropenia
Non-Alcoholic Fatty Liver
  Disease (NAFLD)

Non-Hepatic Cancers
Non-Hodgkins Lymphoma
Non-organ Specific Autoantibodies
Nonresponders / Relapsers
Obesity
Occult HBV Infection
Pathogenesis

Pegasys
PEG-Intron
Pegylated Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1, prothrombin time (PT)
Quality of Life
Quasispecies
Rapid Virologic Response (RVR)
Recurrent HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin Dosing
Risk Factors for HCC
Risk Factors
Roferon
Seroconversion
Sex (gender)
Sexual Transmission
Skin Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission

Transplantation
Undetectable HCV RNA
Viral Eradication
Viral Kinetics
Viral Load
Weight-based Dosing
Women and Children

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


HIV AND AIDS
| HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH
|
TESTS | INTERNET CONFERENCE REPORTS | LINKS | ABOUT US | CONTACT US